Ingavirin® syrup from 6 months
Excellent technique against viruses
An innovative drug for the treatment of influenza (types A and B) and other acute respiratory viral infections (rhinovirus, RS virus, adenovirus, etc.).
The original mechanism of action (it is not an interferon inducer).
It has a wide spectrum of action and is approved for use in influenza and acute respiratory viral infections in children from 6 months of age*.
A convenient reception schedule (1 time per day, 5 days).
High safety profile and level of evidence (10 clinical trials of Ingavirin® have been conducted, meeting international standards of evidence-based medicine with the participation of more than 2,300 people).
Ingavirin® promotes*:
- reducing the viral load;
- accelerated virus elimination;
- reducing the duration of illness;
- reducing the risk of complications.
Indications for use:
Treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection, rhinovirus infection) in adults and children from 6 months of age*.
* Instructions for use of the medicinal product for medical use Ingavirin®, LP-006482